Explains the PSS platform business model centered on the company’s nucleic acid extraction instruments. Proposes a policy to expand recurring revenue by combining ODM and own-brand sales centered on the magnetic-particle nucleic acid extraction technology “Magtration@”. Describes the market outlook for magnetic-particle nucleic acid extraction kits and applications such as IgA nephropathy testing.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7707","jir_company_name":"Precision System Science Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/7707-20260928-01.pdf","jir_short_summary":"Explains the PSS platform business model centered on the company's nucleic acid extraction instruments. Proposes a policy to expand recurring revenue by combining ODM and own-brand sales centered on the magnetic-particle nucleic acid extraction technology \"Magtration@\". Describes the market outlook for magnetic-particle nucleic acid extraction kits and applications such as IgA nephropathy testing.","jir_summary":"### Business Structure and Platform Strategy\nThe PSS platform emphasizes recurring revenue from the combination of instrument \u00d7 reagent \u00d7 consumables, and plans global expansion through both own-brand sales and ODM. With Magtration@ technology at its core, the company highlights a one-stop model that realizes development to mass production of medical devices in a single flow by balancing ODM and own-brand sales. Major partners such as ELITech are cited, explaining a structure to expand into global markets via ODM.\n\n### Market Environment and Growth Opportunities\nThe market for magnetic-particle nucleic acid extraction kits is expected to continue growing post-COVID, and while the top five major players hold approximately 73.5% market share, PSS's current share is about 5.8% (as of 2024). The nucleic acid extraction market is expected to see efficiency improvements through full automation, and new clinical testing demand is anticipated from applications such as glycan analysis for IgA nephropathy testing.","jir_financial_highlights":"","jir_category":"","jir_hashtags":"#share_buyback_related, #long_term_growth_strategy, #ODM_strategy, #Magtration, #IgA_nephropathy_testing, #mid_term_management_plan","jir_key_figures":"Key Figure 1: PSS platform market share of approx. 5.8% as of 2024 (relative figure noted in the PDF)\nKey Figure 2: Overview of test demand for IgA nephropathy testing (background information such as the scale of dialysis patients in Japan)\nKey Figure 3: Description indicating the proportion of recurring revenue in the business model (revenue structure from the instrument \u00d7 reagent \u00d7 consumables platform)","jir_meta_title":"Precision System Science Co., Ltd. \u2014 Business Plan and Growth Strategy | September 2026","jir_meta_description":"PSS centers its business on the magnetic-particle nucleic acid extraction technology Magtration, pursuing global expansion through both ODM and own-brand channels. This document explains the market environment, business plan, and growth opportunities including new applications such as IgA nephropathy testing.","jir_og_title":"PSS Business Plan and Growth Strategy | September 2026","jir_og_description":"Presentation materials explaining PSS's business platform leveraging Magtration magnetic-particle nucleic acid extraction technology, market opportunities, and ODM strategy.","jir_og_image_url":"\/assets\/og\/company-business_update.jpg","jir_chart_data_collection":"[]","ir_related_company":59741,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-123908","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n